Previous 10 | Next 10 |
MALVERN, Pa., March 22, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced it has received a second Complete Response Letter (CRL) from the ...
Noteworthy events during the week of March 24 - 30 for healthcare investors. More news on: Cidara Therapeutics, Inc., Recro Pharma, Inc., Autolus Therapeutics plc, Healthcare stocks news, , Read more ...
Recro Pharma ( REPH ), a smallcap U.S. pharma company has a Food and Drug Administration (FDA) decision on its main drug pending on March 24, 2019 . The chance of approval appears to be approximately 80%, using base rates for drugs at a similar approval stage, and the drug's value, if approve...
MALVERN, Pa., March 12, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced an Industry ‘Lunch and Learn’ Session at the upcoming A...
MALVERN, Pa., March 04, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced that it has closed on an amended and expanded $125 million credit fac...
MALVERN, Pa., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced the publication of clinical data from its Phase III study evaluating t...
MALVERN, Pa., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced the publication of new intravenous (IV) meloxicam data. The arti...
Recro Pharma, Inc. (REPH) Q4 2018 Earnings Conference Call February 19, 2019 08:00 AM ET Company Participants Claudia Styslinger - Investor Relations Gerri Henwood - President & Chief Executive Officer Ryan Lake - Chief Financial Officer John Harlow - Executive Vice Preside...
The following slide deck was published by Recro Pharma Inc in conjunction with this Read more ...
Recro Pharma ( REPH ) Q4 results : Revenues: $17.8M (-6.3%). More news on: Recro Pharma Inc, Healthcare stocks news, Earnings news and commentary Read more ...
News, Short Squeeze, Breakout and More Instantly...
Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging CoreRx to Commence a Tender Offer for all Outstanding Shares of Societal CDMO, Inc. CLEARWATE...
Agreement Broadly Applicable to All Therapeutic Areas with Specific Focus on the Growing Psychedelic and Cannabinoid Drug Development Markets Complementary Capabilities Range from API Manufacturing through Process Development and cGMP Manufacturing to Fill/Finish GAINESVILLE, Ga. ...
Recorded Q3 Revenue of $23.6 Million Signed Multiple New Business Agreements with New and Existing Customers Closed Public Offering Raising Gross Proceeds of Approximately $8.3 Million Initiated Corporate Restructuring; Expected to Result in Annualized Savings of Approxi...